High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered.

摘要: Abstract We examined the influence of aromatization testosterone on serum high-density lipoprotein cholesterol (HDL-C) and postheparin plasma hepatic triglyceride lipase activity (HTLA) in men. Eighteen healthy lean nonsmokers (ages, 20 to 33) were administered androgens a weekly total dose 280 mg for 12 weeks one three groups: enanthate (TE) (280 mg/wk intramuscularly [IM]); TE IM) + testolactone (TL) (250 orally [PO] four times daily); or methyltestosterone (MeT) (20 PO twice daily). Serum achieved steady state levels by 4 with >40 nmol/L (TE TL) 250 pmol/L remained below 70 TL MeT). LH fell less than 5 U/L but unchanged MeT. By weeks, HDL-C had decreased significantly from 1.20 ± 0.13 0.77 mmol/L (MeT), 1.18 0.15 0.89 TL), demonstrated no decrease group across time course study. These changes preceded mean increases HTLA 102% 55% over baseline, significant change TE. The returned baseline within 2 steroid cessation. There cholesterol, triglycerides, insulin any but, MeT group, apo AI low-density (LDL-C) increased. After treatment, sex hormone binding globulin (SHBG) 37% 54% 73% levels; these evident second week treatment following results suggest that has little effect when corresponding increase E2 is prevented, increases. MeT, which not metabolized E2, produced most dramatic increases, even at did reduce LH; thus, specific properties 17-alkylated may further atherogenic potential this class androgens.